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Abstract: Evidence shows that metformin is an antidiabetic drug, which can exert favorable
anti-inflammatory effects and decreased bone loss. The development of nanoparticles for metformin
might be useful for increased therapeutic efficacy. The aim of this study was to evaluate the effect of
metformin hydrochloride-loaded Poly (D,L-Lactide-co-glycolide) (PLGA)/(MET-loaded PLGA) on a
ligature-induced periodontitis model in diabetic rats. MET-loaded PLGA were characterized by mean
diameter, particle size, polydispensity index, and entrapment efficiency. Maxillae were scanned using
Microcomputed Tomography (µCT) and histopathological and immunohistochemical analysis. IL-1β
and TNF-α levels were analyzed by ELISA immunoassay. Quantitative RT-PCR was used (AMPK,
NF-κB p65, HMGB1, and TAK-1). The mean diameter of MET-loaded PLGA nanoparticles was in
a range of 457.1 ± 48.9 nm (p < 0.05) with a polydispersity index of 0.285 (p < 0.05), Z potential of
8.16 ± 1.1 mV (p < 0.01), and entrapment efficiency (EE) of 66.7 ± 3.73. Treatment with MET-loaded
PLGA 10 mg/kg showed low inflammatory cells, weak staining by RANKL, cathepsin K, OPG, and
osteocalcin, and levels of IL-1β and TNF-α (p < 0.05), increased AMPK expression gene (p < 0.05)
and decreased NF-κB p65, HMGB1, and TAK-1 (p < 0.05). It is concluded that MET-loaded PLGA
decreased inflammation and bone loss in periodontitis in diabetic rats.
Int. J. Mol. Sci. 2018, 19, 3488; doi:10.3390/ijms19113488 www.mdpi.com/journal/ijms
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1. Introduction
Polymeric nanoparticles are particles with a diameter between 1 and 1000 nm [1]. In recent years,
nanoparticulate drug release systems using biodegradable polymers have been extensively studied
for various applications [2,3]. Nanoparticles may also offer advantages, such as increased therapeutic
efficacy, prolonged and controlled release of the drug, decreased toxicity, as well as stability and lower
drug decomposition [4,5].
Among the polymers studied for nanoparticle preparation, poly lactic-co-glycolic acid (PLGA)
has been widely used because it is a biocompatible and biodegradable synthetic polymer that has been
approved by the United States Food and Drug Administration (USFDA) [6].
Polymer composition is the most important factor to determine the hydrophilicity and degradation
rate of a delivery matrix. The amount of glycolic acid is a critical parameter in tuning the hydrophilicity
of the matrix and therefore the degradation and drug release rate [7].
Biguanides are an important class of oral hypoglycemic agents and act by inhibiting
gluconeogenesis in the liver, increasing the density of low and high affinity receptors for insulin, and
decreasing resistance to the peripheral effects of insulin [8]. Nanoparticles have been investigated as the
delivery systems for a wide number of drugs. They have the advantages of high stability in lyophilized
or appropriate formulation, feasibility for incorporating both hydrophobic and hydrophilic active
substances, high carrier capacity of many drug molecules, and feasibility for various administration
routes [9]. Metformin is the most widely prescribed oral antihyperglycemic agent for the treatment
of type 2 diabetes [10], as it has a slow and incomplete absorption following oral administration.
The development of drug delivery system (e.g., nanoparticles) strategies for metformin might be useful
to reduce the doses [11].
The treatment in diabetes patients with metformin has shown that there is reduced TNF-α
expression [12], with confirmed anti-inflammatory activity [13]. In periodontal research, animal models
should enable the validation of hypotheses and prove the safety and efficacy of new regenerating
approaches using biomaterials, growth factors, or stem cells. Experimental animal models are critical
tools to investigate mechanisms of periodontal pathogenesis and test new therapeutic approaches.
The ligature-induced periodontitis model has been used frequently in relatively large animals,
including rodents, to assess the host response and its effects on the tooth-supporting tissues (gingiva
and bone) under well-controlled conditions. The use of a ligature-induced periodontitis model is
reliable and reproducible over a period of 10 days in rodents [14]. The effect of metformin on a
periodontal disease experimental model was previously confirmed by our group [15]. However, it is
important to consider that the animals in this study were not diabetic, since our objective was to verify
the pleiotropic effect of metformin in inflammation and bone loss in a periodontal disease experimental
model. Based on these previous findings from our group, our hypothesis is that when metformin is
used in the periodontal disease model in diabetic animals, it would confirm a reduction of inflammation
and bone loss. We believe that the association of metformin with PLGA may confirm the efficacy
of metformin in periodontal disease in diabetic rats and enable us to reduce the metformin dosage,
while maintaining the same efficacy of inflammation control and bone loss. To answer this question,
we aimed to evaluate the effect of metformin hydrochloride-loaded Poly (D,L-Lactide-co-glycolide)
(PLGA) in a ligature-induced periodontitis model in diabetic rats.
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2. Results
2.1. Characterization of Met-Loaded PLGA (Poly Lactic-co-Glycolic Acid) Nanoparticles
The well-defined spherical morphology and smooth surface of free-drug PLGA nanoparticles and
MET-loaded PLGA nanoparticles can be directly observed in an atomic force microscope (AFM) image
(Figure 1). Table 1 showed that the mean diameter of MET-loaded PLGA nanoparticles was in the
range of 457.1 ± 48.9 nm (p < 0.05), with a polydispersity index of 0.285 ± 0.12 (p < 0.05), Z potential of
8.16 ± 1.1 mV (p < 0.01), and entrapment efficiency (EE) of 66.7 ± 3.73 (Table 1). These results suggest
that the addition of MET (metformin) in the core slightly affected the particle sizes (p > 0.05). The mean
particle size of MET-loaded PLGA nanoparticles was slightly larger than that of pure empty PLGA
nanoparticles, indicating the presence of MET in the hydrophilic core of the nanoparticles [16,17].
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The results are expressed as mean ± SD (n = 3); * p < 0.05; ** p < 0.01. 
2.2. Glucose Dosing 
Induction of diabetes occurred in the control groups (diabetes mellitus (DM), PLGA, and 
positive control) and also in all treated experimental groups 1 and 2, and diabetes was confirmed for 
values greater than 300 mL/dL of blood glucose. Glucose levels: Sham group (unbound group), 
periodontal disease (PD) (bound), DM (diabetic group without ligation), PLGA (diabetic group and 
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Figure 1. Ato ic force icroscope (AF ) 2D and 3D i ages. (A) Free drug nanoparticles and (B)
ET-loaded PLGA (metformin-loaded poly lactic-co-glycolic acid) nanoparticles. The topography was
observed in water with a frequency shift of 1 Hz and a cantilever oscillation amplitude of 2 µm × 2 µm.
The scale indicates the topographic height.
Table 1. Loading efficiency of metformin-loaded PLGA (metformin-loaded poly lactic-co-glycolic acid)
nanoparticles by double emulsification.
Formulation Particle Size (nm) PDI Zeta Potential (mV) EE (%)
NP Empty 406.3 ± 14.5 0.187 ± 0.01 −1.51 ± 3.2 −
NP + MET 457.1 ± 48.9 * 0.285 ± 0.12 * 8.16 ± 1.1 ** 66.7 ± 3.73
Notes: NP, nanoparticles; PDI, polydispersity index; MET, metformin; EE, encapsulation efficiency. The results are
expressed as mean ± SD (n = 3); * p < 0.05; ** p < 0.01.
2.2. Glucose Dosing
Induction of diabetes occurred in the control groups (diabetes mellitus (DM), PLGA, and
positive control) and also in all treated experimental groups 1 and 2, and diabetes was confirmed
for values greater than 300 mL/dL of blood glucose. Glucose levels: Sham group (unbound group),
periodontal disease (PD) (bound), DM (diabetic group without ligation), PLGA (diabetic group
and with ligation/PLGA DM + PD, diabetic group and with ligation/water), Met 50 (group bound
and treated with MET 50 mg/kg), Met 100 (bound and treated group with MET 100 mg/kg),
PLGA + 100 mg/kg Met 100 mg/kg + PLGA) and PLGA + 10 mg/kg Met (group bound and treated
with MET 10 mg/kg + PLGA). Only treatment with PLGA + 10 mg/kg Met significantly reduced
systemic glucose levels in the animals (286.5 ± 109.6 mg/dL, compared with DM (605 + 52.16 mg/dL)
and positive control (529.9 + 76.78 mg/dL), p < 0.001, Table 2).
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Table 2. Glucose of animals/group, Natal, RN, Brazil, 2018.
Groups Glucose mg/dL (Mean± Standard Deviation)
Sham 115.7 ± 18.86 a ***, b ***
PD 176.7 ± 90.4 a ***, b ***
DM 605 ± 52.16
Positive control/(PD + DM) 529.9 ± 76.78
Met 50 523.2 ± 31.74
Met 100 522.0 ± 78.32
PLGA 512 ± 56.02
PLGA + 10 mg/kg Met 286.5 ± 109.6 a ***, b ***
PLGA + 100 mg/kg Met 440 ± 59.9
a = Difference among groups and DM, b = difference among groups and positive control/PD + DM (Periodontal
disease + Diabetes mellitus), *** p < 0.001.
2.3. Histopathological Analysis
Histopathological data for the Sham and DM control groups showed that infiltration of
inflammatory cells was absent or scarce and was restricted to the marginal gingival region, and
that the alveolar bone and cement were preserved with scores 0 (0–0) for both groups; the difference
was significant when compared to the PD, PLGA control, and positive control groups (p < 0.001),
Figures 2 and 3. The PD, PLGA control, and positive control groups presented scores of 2.8 (2.5–3.0),
3 (3–3), and 3 (3–3), respectively, with presence of marked infiltration of inflammatory cells in the
gingiva and periodontal ligament, marked degradation of the alveolar bone, and partial to severe
destruction of dental cement, Figures 2 and 3. The experimental groups Met 50, score: 3 (1.5–3), and
PLGA + 100 mg/kg Met, score 3 (2–3) showed a marked inflammatory infiltrate in the gingiva and
periodontal ligament, marked degradation of the alveolar process, and partial to severe destruction
of the cement, Figures 2 and 3. In turn, the experimental groups Met 100, score: 2 (1.5–3) indicated
marked cellular infiltration in the gingiva and periodontal ligament, moderate degradation of the
alveolar process, and low cementation, Figures 2 and 3. On the other hand, the PLGA + 10 mg/kg Met,
score 2 (1.5–2.5) group indicated moderate inflammatory cellular infiltrate throughout the gingival
insertion, light alveolar resorption, and intact cement, with a significant reduction in bone loss when
compared to the positive control group (p < 0.05), Figures 2 and 3.
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without PD: Displaying usual aspects; (D) DM group with PD: Positive control; (E) Met 50 group; (F) 
Met 100 group: Lower scores; (G) PLGA (DM group with PD); (H) DM group with PD + PLGA + 10 
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Figure 2. i i alyses. Histopath logic l aspects of th periodontal c ntrol and treated
groups. (A) Sham Group: Displaying usual aspects; (B) PD group without DM; (C) DM group without
PD: Displaying usual aspects; (D) DM group with PD: Positive control; (E) Met 50 group; (F) Met 100
group: Lower scores; (G) PLGA (DM group with PD); (H) DM group with PD + PLGA + 10 mg/kg
Met group; and (I) DM group with PD + PLGA + 100 mg/kg group. Disorganization of connective
tissue and intense inflammatory infiltrate (**); alveolar bone destruction (***); (I) destruction of cement;
(→) Giant multinucleated cell; a: Alveolar bone; c: Cement; d: Dentin; p: Pulp; tc: Connective tissue.
* p < 0.05, ** p < 0.01, *** p < 0.00. Hematoxylin and eosin stain (H&E), 200×; PD = periodontal disease;
DM = diabetes mellitus.
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Quantification of gene expression for the inflammatory NF-κB p65 transcription factor showed a 
significant reduction for the PLGA + 10 mg/kg Met groups (p < 0.05) compared to the positive 
control, Figure 5. Quantification of the gene expression of protein kinase AMP-activated catalytic 
subunit α 1 (AMPK) showed a significant increase in this transcription factor for diabetic animals 
and periodontal disease treated with PLGA + 10 mg/kg Met when compared to the positive control 
Figure 3. Histopathological score. Sham Group, PD group without DM; DM group without PD;
DM group with PD: positive control; Met 50; Met 100; PLGA + 10 mg/kg Met; PLGA + 100 mg/kg.
* p < 0.05; *** p < 0.001. (Kruskal–Wallis test followed by Dunn’s test).
2.4. Cytokines
The quantification of inflammatory cytokines showed a significant reduction of IL-1β and TNF-α
in the Sham group when compared to the positive control group (p < 0.01 and p < 0.001, respectively).
The quantification of TNF-α showed a significant increase in the PD when compared to the Sham
group (p < 0.001). The PLGA + 10 mg/kg Met treatment significantly reduced the IL-1β and TNF-α
levels when compared to the positive control group (p < 0.05), Figure 4.
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Figure 4. IL-1β and TNF-α levels in Sham, PD; positive control; Met 50; Met 100; PLGA + 10 mg/kg
Met; PLGA + 100 mg/kg. * p < 0.05, ** p < 0.01, *** p < 0.001. Analysis of variance/ANOVA test
followed by Bonferroni test.
2.5. RT-PCR
Quantification of gene expression for the inflammatory NF-κB p65 transcription factor showed
a significant reduction for the PLGA + 10 mg/kg Met groups (p < 0.05) compared to the positive
control, Figure 5. Quantification of the gene expression of protein kinase AMP-activated catalytic
subunit α 1 (AMPK) showed a significant increase in this transcription factor for diabetic animals
and periodontal disease treated with PLGA + 10 mg/kg Met when compared to the positive control
and PLGA + 100 mg/kg Met (p < 0.05) groups, Figure 5. Quantification of HMGB1 gene expression
showed a significant reduction for the PLGA + 10 g/kg et groups (p < 0.05) when compared to the
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positive control, Figure 5. The quantification of TAK1 gene expression showed a significant reduction
for the PLGA + 10 mg/kg Met groups (p < 0.05) when compared to the positive control, Figure 5.
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comparing positive control (0.97 ± 0.35 mm) to PLGA 10 mg/kg Met (0.48 ± 0.14 mm) treatment.
PLGA + 100 mg/kg Met showed bone loss (0.81 ± 0.28 mm) (Figure 6).
2.7. Immunohistochemistry
The sham group showed immunostaining absence for RANK, RANKL, OPG, and cathepsin, and
low staining for osteocalcin. The positive control group showed intense immunostaining for RANKL
and cathepsin, more significantly than the Sham group (p < 0.001) and the PLGA + 10 mg/kg Met
group (p < 0.05). The PLGA + 10 mg/kg Met treatment resulted in low staining of RANKL, OPG,
osteocalcin, cathepsin, and osteocalcin (Figures 7 and 8). Immunohistochemical analysis revealed
nuclear and cytoplasmic immunoexpression in periodontal connective and bone tissue cells with a
diffuse pattern of expression for all proteins in the evaluated specimens, with increased expression
in the PLGA + 10 mg/kg Met group compared to positive control. Immunoreactivity to RANK
was predominantly observed in osteocytes. RANK-L presented immunoexpression in osteocytes,
osteoclasts, and mononuclear inflammatory cells. OPG demonstrated immunostaining in mononuclear
inflammatory cells, osteoclasts, and also in osteoblasts present in the PLGA + 10 mg/kg Met group,
where an area suggestive of osteoblastic paving was observed. Expression for osteocalcin was
present in mononuclear inflammatory cells and cathepsin revealed immunoexpression in mononuclear
inflammatory cells and osteocytes.
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3. Discussion
Polylactic acid contains an asymmetric α-carbon which is typically described as the D or L
form in c ssi l stereochemical terms. The enantiomer forms of the polym r polylactide (PLA)
are poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). PLGA is generally an acronym for
poly D,L-lactic-co-glycolic acid, where D- n L-lactic acid form ar in equal ratio [7]. PLGA can
be processed int almost any shape size, and an encapsulate molecules f virtually any siz .
The mecha ical strength of PLGA is affected by physical properties, s ch as molecular weight and
polydispersity i dex [7]. These properti s also affect the ability to be formulated as a drug delivery
device and may control the device degradation rat and hydrolysis. When copolymerized with PLA,
crystalli e pol lactide (PGA) reduc s the cryst llinity deg ee of PLGA and, as a result, increases
the hydration and hydrolysis rates. As a rule, higher PGA content lea s to quicker degr dation
rates, with an exception of 50:50 r tio of PLA/PGA, which exhibits the fast st degradation with
hig er PGA content leading to an increased degradation interval below 50 [18]. It has a slow and
incomplet absorption f llowing or l administr ti , a d epeat d applications of high metformin
doses ar needed for effective treatment, due to its short biologic l half-life. The development of drug
elivery syst m (e.g., nanoparticles) strategies for metformin might be use ul to reduce the doses and
osing frequenc [11]. Results of cellular and mitochond ial uptake showed that the metformin-solid
lipid n oparticles (SLNs) were easier to uptake in cells and mitochondria than the pure metformin
group [19]. In this study, MET-loaded PLGA nanopa ticles with a 50:50 ratio were i the range of
457.1 ± 48.9 nm, with a polydispersi y index of 0.285, Z potenti l f 8.16 ± 1.1 mV, and entrapm nt
effici ncy (EE) of 66.7%. These results suggest that the additi n of MET in he core slightly affected the
particle sizes.
Our data showed that the association of metformin with PLGA was able to reduce glucose levels of
529.9 dL/mL3 (positive con rol group) to 286. 5 dL/mL3 (MET 10 + PLGA group), demonstrating that
the incorporation of drugs into nanoparticles may improve the drug efficacy [17]. A low polydispersion
coefficient guarantees greater control in the size particle d, consequently, in the drug release that the
system can supply in biological fluids [7]. Once in th bloodstream, nanoparticl s tend to accumulate
in places of high bloo perfusion, such as organs, tissues affected by inflammation, and tumors [20].
It is interesting to highlight that we used the same formulati n in two different dilutio s
(PLGA + 10 mg/kg MET or PLGA + 100 mg/kg Met groups). Some drawbacks of the enhanced
permeability and retention (EPR) effect of nanoparticl s corroborate these phenomena. When a large
amount of hydrophobic nanoparticles is administered in a short volume of medium (as occurs w h
a dose of PLGA + 100 mg/kg Met), their accumulation in a specific administration site is possible,
reducing the surface area and, consequently, the drug diffusion rate [21]. Their drug response is not
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necessarily dose-dependent and linear, but is dependent on the drug release rate that the polymeric
system can supply in a biological medium [22–24], and is not necessarily dose-dependent. The lower
doses can have the benefit of the EPR effect, as the released drug is able to diffuse more easily.
These results indicate that incorporation of the drug into the nanoparticle has systemic benefits, thus
favoring glycemia control with a dose reduction of metformin.
PLGA is the most successful and most featured polymer for drug-controlled release systems.
The effects of the combination of metformin and PLGA can be observed in both the inflammatory
process and in the reduced bone loss in periodontal disease. The histopathological findings show a
reduction of the inflammatory infiltrate, little destruction of the periodontal ligament, and absence of
dental cement impairment in the group treated with metformin at the dose of 10 mg/kg + PLGA.
This association showed excellent results in periodontal disease in diabetic animals; clinical
and histopathological data corroborate the findings that elucidate the main cellular and molecular
mechanisms involved in controlling inflammation and bone loss in periodontal disease.
In general, drugs are small enough molecules to cross the endothelium in almost all regions
of the body after systemic administration, and can reach both target regions and other healthy
regions not affected by any disease, thus causing associated side effects of medication. The use
of colloidal nanoparticle systems helps to control these adverse effects and improves therapeutic
efficacy. These drugs are encapsulated within nanoparticles of 50–800 nm, which are not able to
cross vessel walls of healthy regions of the body (the space between these cells is only 15–30 nm) [25].
Nanoformulation also demonstrates increased anti-inflammatory effects and drug retention at the
action site [26]. The present study showed that all groups treated with metformin significantly reduced
the inflammatory markers (IL-1β and TNF-α) with a prominence of MET 10 mg/kg + PLGA.
The RANKL, RANK, and OPG system represents the key molecular regulation of bone
remodeling [27]. Studies have shown a favorable effect of metformin on bone formation. There are two
action mechanisms suggested for the osteogenic effect of metformin, which are increased osteoblast
proliferation and decreased osteoclast activity. Studies indicate that the proliferation of Metformin is
increased after its absorption by osteoblasts [28]. This drug negatively regulates RANKL production
and positively regulates osteoprotegerin (OPG) production from osteoblasts [29]. Thus, there is a
decrease in osteoclast activity through this decrease in the RANKL/OPG ratio, aiding in inducing
bone formation and inhibiting resorption [30]. In our study, it was found in vivo that metformin, at the
dose of 10 mg/kg + PLGA, reduced bone loss with increased osteocalcin immunoblotting and reduced
RANKL, indicating an increase in mature osteoblasts and a reduction in the number of osteoclasts.
AMP-activated protein kinase (AMPK) has emerged as a detection mechanism in regulating
cellular energy homeostasis and is an essential mediator of the central and peripheral effects of
many hormones in glucose metabolism [31]. It is a key molecule in controlling metabolic diseases,
such as type 2 diabetes and obesity, and is activated by antidiabetic drugs, such as metformin and
thiazolidinediones [32]. Most isoforms of AMPK subunits are expressed in bone cells and bone tissue.
It was observed in vitro that metformin (50 µM) significantly increased the expression of osteocalcin,
stimulated alkaline phosphatase activity, and increased cell mineralization, yet significantly activated
AMPK in a dose- and time-dependent manner [33]. AMPK plays a critical role as a negative feedback
regulator of RANKL osteoclast formation promoting action [34]. Araújo et al. (2017) [15] demonstrated
that a low dose of metformin reduced bone loss, decreased RANKL, and increased the relative
expression of AMPK mRNA. Osteocalcin is specifically expressed in osteoblasts, secreted in circulation,
and can regulate glucose homeostasis. Metformin stimulates the expression of osteocalcin and the
differentiation of osteoblasts via AMPK activation [33]. In our study, it was observed that MET
10 mg/kg + PLGA activated AMPK gene expression, which led to stimulated osteocalcin expression
and, consequently, osteoblast deposition and bone formation. On the other hand, the increase of AMPK
contributed to weak immunolabeling of RANKL and, consequently, of the osteoclast activity.
Lee et al. 2010 [34] demonstrated that AMPK acts via CaMKK and TAK1 activation to serve as
a negative feedback regulator of RANKL-induced osteoclast formation. Mizukami et al. [35] also
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reported that RANKL stimulation facilitates the formation of a complex containing RANK, TRAF6,
TAB2, and TAK1, leading to the activation of TAK1. RANKL also acts through TRAF6 to activate
TAK1, promoting osteoclastogenesis via NF-κB activation. More interestingly, CaMKK and TAK1 can
be activated by RANKL in osteoclast precursors.
HMGB1 acts by stimulating the differentiation of osteoclast precursors in the presence of RANKL,
and has similar proinflammatory properties to cytokines once it enters the extracellular space [36].
Thus, in our study, we were able to observe a reduction in HMGB1 at the dose of MET 10 mg/kg, thus
showing its relation with inflammation control and in bone loss, since it contributed to a decrease the
NFKβ and RANKL levels.
This study showed that the PLGA + 10 mg/kg Met association had better results, as it managed
to control blood glucose levels below what is considered diabetes, and so this nanotechnology product
guaranteed rational release of the drug at the inflammation site, thereby controlling inflammation and
bone loss in the experimental periodontal disease model.
4. Material and Methods
Metformin hydrochloride was purchased from Companhia da Fórmula, D,L-PLGA 50:50 (inherent
viscosity of 0.63 dL·g−1 at 30 ◦C) was purchased from Birmingham Polymers Inc. (Birmingham,
AL, USA), polyvinyl alcohol (PVA) was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA),
and dichloromethane (DCM) from QHEMIS® (Indaiatuba, Brazil). Purified water (1.3 µS·cm−1) was
prepared from reverse osmosis purification equipment, (OS50 LX Gehaka, São Paulo, Brazil). All other
reagents were of analytical grade.
4.1. Experimental Design and Preparation of MET-Loaded PLGA Nanoparticles
PLGA nanoparticles for metformin encapsulation were fabricated by adapting the double
emulsion solvent diffusion method [37] with some modifications: 50 mg of PLGA was dissolved
in 6 mL of dichloromethane (DCM). Metformin (272 mg/mL) was dissolved in an aqueous phase
containing 0.1% polyvinyl alcohol. The aqueous phase with the drug (600 µL) was added into 3 mL
of organic phase containing PLGA. The mixture was emulsified with a probe-tip sonicator (probe-tip
diameter: 1.3 cm, Sonics & Materials Inc., Danbury, CT, USA) operating at 50% amplitude intensity
for 1 min. This first mixture was then added into 6 mL of water containing 1.0% of PVA and the
mixture was emulsified with a probe-tip sonicator for 1 min. This emulsion was added into 8 mL of
water containing 1.0% PVA under magnetic stirring, leading to the formation of a Water/Oil/Water
(W/O/W) emulsion with MET-loaded PLGA nanoparticles. The organic solvent was evaporated
overnight by magnetic stirring. Free-drug nanoparticles were prepared using the same procedure, but
excluding the drug.
4.2. Physicochemical Aspects
The measurements of mean diameter and particle size distribution were assessed by dynamic
light scattering in a ZetaPlus device (Brookhaven Instruments Co., New York, NY, USA) equipped
with a 90Plus/BI-MAS apparatus at a wavelength of 659 nm, with a scattering angle of 90◦. Z potential
of the particles was measured by laser Doppler anemometry using the same equipment. All analyses
were performed at 25 ◦C. Experimental values were given as the mean ± SD for the experiments
and carried out in triplicate for each sample. The shape and surface of drug-free and MET-loaded
nanoparticles were observed using AFM images. The dispersions were freshly diluted with purified
water at a ratio of 1:25 (v/v) and dropped in a cover slip, dried under a desiccator for 24 h and then
analyzed in a Shimadzu SPM-9700 AFM (Tokyo, Japan) at room temperature with a cantilever in
noncontact mode at 1 Hz scanning. Samples were prepared using one drop of dispersion, which was
placed on a washed microscope slide and dried under a desiccator for 24 h, and then analyzed at 25 ◦C
in a cantilever in noncontact mode.
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4.3. Drug Loading Efficiency
PLGA nanoparticles were used in this experiment to obtain an efficient drug loading
corresponding to 6 mg/mL. Metformin hydrochloride-loaded Poly (D,L-Lactide-co-glycolide) (PLGA)
nanoparticles (NPs) were assessed by an indirect method, in which dispersions were centrifuged at
16,900 RCF (g) per 60 min at 4 ◦C using an ultra-centrifugal filter (Sartorius®, Vivaspin 2, Ultra-15
MWCO 10 kDa). The supernatant was removed and diluted in purified water 1:20 (v/v) and the
measurements were carried out in a UV Thermo Fisher Scientific 60S Evolution Spectrophotometer
(Waltham, MA, USA), using previously validated UV spectrophotometry at 232 nm. Entrapment
efficiency (EE) was calculated using the following equation: EE% = (total drug—drug determined in
the supernatant)/total drug × 100.
4.4. In Vivo Experimental Study (Periodontal Disease Experimental Model)
The experiments were performed on male Wistar rats (180–220 g) housed under standard
conditions (12 h light/dark, 22 ± 0.1 ◦C), with ad libitum access to food and water. All animal
protocols were approved by the Animal Ethics Committee of the Federal University of Rio Grande
do Norte (CEUA, Permit No.: 046/2017, 7 November 2017), Brazil. The anesthesia used to induce
periodontal disease by intraperitoneal administration was Ketamine 10% (70 mg/kg, Vetnil, São Paulo,
Brazil) and 2% xylazine (10 mg/kg, Vet Brands International, São Paulo, Brazil). The animals were
euthanized with 80 mg/kg thiopental (Cristália, São Paulo, Brazil).
4.5. Control and Experimental Groups
Control Groups:
Twenty animals without diabetes and without periodontal disease (Sham)
Twenty animals with periodontal disease and without diabetes (PD)
Twenty animals with diabetes and without periodontal disease (DM)
Twenty animals with diabetes and with periodontal disease and treatment with vehicle water
(Positive Control). This group, called the Positive Control group, was used to compare with all groups,
because it has diabetes and periodontal disease (Positive Control group).
Six animals with diabetes and with periodontal disease and treatment with vehicle: PLGA
(PLGA Control); this group was used to confirm the same results of the Positive Control group by
histopathological analysis.
We decided to use the Positive Control group as a standard for all other analyses, avoiding
excessive use of animals (following the principles of 3Rs).
Experimental groups 1: Metformin hydrochloride
Twenty animals with diabetes and with periodontal disease and Metformin 50 mg/kg/day DOSE
(Met 50)
Twenty animals with diabetes and periodontal disease and Metformin 100 mg/kg/day DOSE
(Met 100)
Experimental groups 2: Metformin hydrochloride-loaded Poly (D,L-Lactide-co-glycolide) (PLGA)
nanoparticles (NPs)
Using the best histopathological results from experimental groups 1, we defined metformin
hydrochloride-loaded Poly (D,L-Lactide-co-glycolide) (PLGA) nanoparticles (NPs) (with periodontal
disease and diabetes). The best anti-inflammatory dose of Experimental groups 1 was used and a
lower 10× dose of metformin (best anti-inflammatory dose of Experimental groups 1) was used.
Twenty animals with diabetes and periodontal disease and 100 mg/kg/day of Metformin-loaded
PLGA (PLGA + 100 mg/kg Met).
Twenty animals with diabetes and with periodontal disease and 10 mg/kg/day of
Metformin-loaded PLGA (PLGA + 10 mg/kg Met).
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4.6. Diabetes Induction
Diabetes was induced by administration of Streptozotocin/STZ (Sigma-Aldrisch) (40 mg/kg,
ip) through the penile vein, dissolved in sodium citrate buffer (0.01 M, pH 4.5) at the concentration
of 40 mg/kg body weight under general anesthesia, with 3% isoflurane inhalation. Glucose was
measured by a glycosometer (one touch select simple) after one week of STZ administration. Upon
reaching plasma glucose stability of ≥300 mg/dL, the animals were considered diabetic and selected
for later periodontal disease studies. A puncture was made in the initial portion of the animal’s tail
using a sterile needle and the blood was collected on a reagent strip for glucose determination.
4.7. Periodontal Disease Induction
After diabetes confirmation, periodontal disease induction was performed by placing a 3.0 nylon
wire on the second left molar of male Wistar rats with the animals under i.p. ketamine (80 mg/kg) and
xylazine (10 mg/kg) anesthesia. Oral treatments were performed by gavage 30 min prior to periodontal
disease induction, which continued until the 10th day. Euthanasia by thiopental (80 mg/kg) was
performed on the 11th day. After sacrificing the animals, the gingival and maxillary tissue samples
were sent for analysis.
4.8. Histopathological Analysis (Decalcified Tissue)
Histological analyzes were independently performed by two calibrated pathologists. All groups
(controls and experimental) were analyzed by histopathology. This step selected the best results that
were used for the subsequent analyses. The sectioning was performed in the morphology laboratory
of the UFRN, and the slides were analyzed by light microscopy in the department of Morphology. Five
jaws were used per group. Alveolar bone specimens were collected, fixed in 10% buffered neutral
formol, and demineralized in 5% nitric acid. The samples were then dehydrated, embedded in paraffin
and sectioned along the molars in the mesiodistal plane for hematoxylin and eosin. Sections (4 µm)
corresponded to the area between the first and second maxillary molars, where ligation was placed
for analysis by light microscopy (40×magnification). Influx of inflammatory cells and alveolar bone
integrity and cement were analyzed. A score of 0 indicated that infiltration of inflammatory cells
was absent or scarce and was restricted to the marginal gingival region, and that the alveolar process
and cement were preserved; a score of 1 indicated moderate cell infiltration throughout the gingival
insert, minor alveolar resorption, and intact cement; a score of 2 indicated marked cellular infiltration
in the gingiva and periodontal ligament, marked degradation of the alveolar process, and partial
destruction of the cement; and 3 indicated marked cellular infiltration, complete reabsorption of the
alveolar process, and severe destruction of the cement.
4.9. Elisa Immunoassay for Detection of IL-1β and TNF-α
Gingival tissues (n = 5) of the control (Sham, PD, and positive control) and experimental
groups were stored at −70 ◦C. IL-1β levels (detection range: 62.5–4000 pg/mL; lower detection
limit: 12.5 ng/mL of recombinant mouse IL-1β) and TNF-α (detection range: 62.5–4000 pg/mL; lower
limit of detection: 50 ng/mL mouse TNF-α recombinant) were determined using commercial ELISA
kits (R&D Systems, Minneapolis, MN, USA), as previously described [15]. All samples were measured
at 490 nm.
First, microtiter plates were coated overnight at 4 ◦C with rat antibodies against IL-1β and TNF-α.
Plates were then blocked, samples and standards added in several dilutions, in duplicate and incubated
at 4 ◦C for 24 h. The plates were washed three times with buffer and the antibodies were added to the
wells (anti-TNF-α or anti-IL-1β, sheep biotinylated polypropylene, diluted 1000 with 1% BSA assay
buffer). Plates were incubated at room temperature for 1 h, washed, and 50 µL of avidin-HRP (1:200)
µL were added. Then, O-phenylenediamine reagent coloring (50 mL) was added 15 min later, and the
plates were incubated in the dark at 37 ◦C for 15–20 min. The absolute quantitative of IL-1β and TNF-α
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to control (PD and Positive control) and experimental groups was calculated using the comparison
with the control group (Sham). The enzymatic reaction was reduced with H2SO4 and the absorbance
measured at 490 nm. Values were expressed in pg/mL.
Genetic Marker Rt-PCR Analysis for Periodontal Disease in Diabetic Animals
The control (sham and positive control) and experimental groups (PLGA + 100 mg/kg Met and
PLGA + 10 mg/kg Met) were included in the quantification of expression by RT-PCR. Total RNA from
the gingival tissues of the treated groups was extracted using the Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s guidelines and stored at −70 ◦C.
RNA concentration was determined from the optical density at a wavelength of 260 nm
(using an OD260 unit equivalent to 40 µg/mL RNA). Five micrograms of isolated total RNA were
reverse transcribed to cDNA in a reaction mixture containing 4 µL 5× reaction buffer, 2 µL dNTP
mixture (10 mM), 20 units of RNase inhibitor, 200 units of avian-myeloblastosis virus (AMV)
reverse transcriptase, and 0.5 µg oligo (dT) primer (High-Capacity cDNA Reverse Transcription
Kit, Foster City, CA, USA) in a total volume of 20 µL. The reaction mixture was incubated at
42 ◦C for 60 min, and the reaction was terminated by heating at 70 ◦C for 10 min. The cDNA
was stored at −80 ◦C until further use. Gene expression was evaluated by PCR amplification
using primer pairs based on published rat sequences (GADPH-Rattus norvegicus: Forward primer:
AACTTGGCATCGTGGAAGG, Reverse Primer: GTGGATGCAGGGATGATGTTC; AMPK-Rattus
norvegicus protein kinase, AMP-activated, α 2 catalytic subunit (Prkaa2), mRNA: Forward primer:
AGCTCGCAGTGGCTTATCAT, Reverse Primer: GGGGCTGTCTGCTATGAGAG; NF-κB p65-Rattus
norvegicus v-rel avian reticuloendotheliosis viral oncogene homolog A (Rela), mRNA Forward primer:
5′-TCTGCTTCCAGGTGACAGTG-3′, Reverse Primer: 5′-ATCTTGAGCTCGGCAGTGTT-3′;
HMGB1-Rattus norvegicus high mobility group box 1 (HMGB1), mRNA: Forward primer:
5′-GAGTACCGCCCAAAAATCAA-3′, Reverse Primer: 5′-TTCATCCTCCTCGTCGTCTT-3′;
TAK-1 Forward primer: 5′-GTCATCCAGCCCTAGTGTCAGATT-3′, Reverse Primer:
5′-TTCTTTGGAGTTTGGGCACG-3′. Transforming Growth Factor β-activated Kinase 1 TAK-1-Mus
musculus, mRNA: Forward primer: 5′-GTCATCCAGCCCTAGTGTCAGAAT-3′, Reverse Primer:
5′-TTCTTTGGAGTTTGGGCACG-3′.
Quantitative RT-PCR was performed using Power SYBR Green master mix (Applied Biosystems,
Waltham, MA, USA), and a Step One Plus thermocycler (Applied Biosystems), according to the
manufacturer’s instructions. For the 1× PCR master mix, 2.5 µL of each cDNA was added in a final
volume of 20 µL. The PCR conditions were as follows: 95 ◦C for 5 min, 40 cycles of 30 s at 95 ◦C, 30 s at
52–60 ◦C (based on the target), and 60 s at 72 ◦C. The relative quantitative fold change compared with
the control (Sham) was calculated using the comparative Ct method, where Ct is the cycle number
at which fluorescence first exceeds the threshold. The Ct values from each sample were obtained by
subtracting the values for GADPH Ct from the target gene Ct value. The specificity of resulting PCR
products was confirmed by melting curves.
4.10. Radiographic Microcomputed Tomography (Micro-CT) Measurement of Abl
In this stage, the control groups (Sham and positive control) and experimental groups
(PLGA + 100 mg/kg Met and PLGA + 10 mg/kg met) were included. Animals were euthanized
at the end of the experiment (10 days after addition of the ligature and first drug treatments); maxillae
were dissected and fixed in 10% buffered formalin for 24 h and stored in 70% alcohol. Rat maxillae were
scanned using microcomputed tomography (µCT, micro-CT) (Model 1172; SkyScan, Kontich, Belgium)
at 20 micrometers resolution. Micro-CT files were converted to Digital Imaging and Communications
in Medicine (DICOM) files and imported into Dolphin® software (Toronto, ON, Canada, Version 6.5)
for linear bone height analysis. Linear bone height analysis was performed by positioning the second
molar cementoenamel junctions (CEJ) parallel to each other in the coronal plane. In the axial plane, the
middle of the crown was identified and linear bone distances were recorded on the mesial aspect of
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the second molar on the sagittal image. Additional measurements were taken 0.3 mm palatal from
the middle of the crown, again recording the mesial aspect of the second molar on the sagittal image.
The linear measurements were recorded from the CEJ to the alveolar crest (AC). Each second molar
received a total of two measurements, and these values were averaged for each group. The images
were analyzed using CTAn (V.1.16 Bruker, Billerica, MA, USA). A 40-slice volume set at a threshold of
75 in the bifurcation area of the second molar was used as a region of interest for analysis (n ≥ 3/group
for all µCT analyses).
4.11. Immunohistochemistry
Only the controls (Sham and positive control) and the experimental group
(PLGA + 10 mg/kg met) were included in this step. Fine sections of periodontal tissue (4 µm)
(3 mandibles per group) were produced using a microtome and transferred onto gelatin coated
slides. Each section was deparaffinized and rehydrated. Gingival and periodontal tissues were
washed with 0.3% Triton X-100 in phosphate buffer, then extinguished with peroxidase (3% hydrogen
peroxide) and incubated with the following primary antibodies (Santa Cruz Biotechnology, Interprise,
Brazil) overnight at 4 ◦C: RANKL, 1400; OPG, 1400; cathepsin K, 1400; and osteocalcin, 1400, which
were washed with phosphate buffer and incubated with streptavidin-HRP-conjugated secondary
antibodies (Biocare physicians, Concord, CA, USA) for 30 min, and immunoreactivity for RANK,
RANK-L, OPG, cathepsin K, and osteocalcin were visualized using a colorimetric detection kit
following the manufacturer’s instructions (TrekAvidin-HRP Label, Biocare Medical, Pacheco, CA,
USA; TrekAvidin-HRP Kit, Dako, Carpinteria, CA, USA).
4.12. Statistical Analysis
Using nanoparticle characterization, pairwise comparisons of the analytical data were performed
using the Student’s t-test. One-way analysis of variance (ANOVA) was applied for multiple
comparisons, followed by Tukey’s post hoc test. p < 0.05 was considered statistically significant.
Data for the in vivo experiments were analyzed using descriptive and analytical statistics. Parametric
tests, such as ANOVA, followed by Bonferroni’s post-test and nonparametric Kruskal–Wallis test were
used. A significance level of 5% was considered.
Author Contributions: Conceptualization, A.d.S.B.F.P., G.A.d.S.B., and A.A.d.A.; Data curation, G.A.d.S.B. and
A.A.d.A.; Formal analysis, G.A.d.S.B. and A.A.d.A.; Funding acquisition, A.A.d.A.; Investigation, A.d.S.B.F.P.,
M.L.d.S.L., A.A.d.S.J., E.d.S.S., A.A.d.R., R.H.B., M.G., F.Q.P., R.F.d.A.J., C.A.C.X.d.M., G.C.B.G., and A.A.d.A.;
Methodology, A.d.S.B.F.P., M.L.d.S.L., A.A.d.S.J., E.d.S.S., A.A.d.R., R.H.B., M.G., F.Q.P., R.F.d.A.J., C.A.C.X.d.M.,
G.C.B.G., and A.A.d.A.; Project administration, A.A.d.A.; Supervision, G.A.d.S.B., F.Q.P.,R.F.d.A.J., and
A.A.d.A.; Validation, A.d.S.B.F.P.; Visualization, A.A.d.A.; Writing—original draft, A.d.S.B.F.P. and A.A.d.A.;
Writing—review & editing, A.d.S.B.F.P. and A.A.d.A.
Funding: This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico
(CNPq; 401838/2016-1).
Acknowledgments: This research was supported by Grants from the CNPq (401838/2016-1). The authors are
grateful to COMPANHIA DA FÓRMULA for kindly providing the Metformin hydrochloride.
Conflicts of Interest: The authors declare no conflicts of interest.
Abbreviations
PLGA Poly (D,L-Lactide-co-glycolide)
NPs Nanoparticles
Met Metformin
AFM Atomic force microscopy
EPR Enhanced permeability and retention effect
µCT Microcomputed tomography
Int. J. Mol. Sci. 2018, 19, 3488 15 of 16
References
1. Freichels, H.; Danhier, F.; Préat, V.; Lecomte, P.; Jérôme, C. Fluorescent labeling of degradable
poly(lactide-co-glycolide) for cellular nanoparticles tracking in living cells. Int. J. Artif. Organs 2011,
34, 152–160. [CrossRef] [PubMed]
2. Jia, L. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: Approaches
experimental evidences and theory. Curr. Nanosci. 2005, 1, 237–243. [CrossRef] [PubMed]
3. Lai, F.; Schlich, M.; Pireddu, R.; Corrias, F.; Fadda, A.M.; Sinico, C. Production of nanosuspensions as a tool
to improve drug bioavailability: Focus on topical delivery. Curr. Pharm. Des. 2015, 21, 6089–6103. [CrossRef]
[PubMed]
4. Sharma, A.; Madhunapantula, S.V.; Robertson, G.P. Toxicological considerations when creating nanoparticle
based drugs and drug delivery systems? Expert Opin. Drug Metab. Toxicol. 2012, 8, 47–69. [CrossRef]
[PubMed]
5. Liu, K.C.; Yeo, Y. Extracellular stability of nanoparticulate drug carriers. Arch. Pharm. Res. 2014, 37, 16–23.
[CrossRef] [PubMed]
6. Zhou, Y.; Zhang, L.; Zhao, W.; Wu, Y.; Zhu, C.; Yang, Y. Nanoparticle-mediated delivery of TGF-β1 miRNA
plasmid for preventing flexor tendon adhesion formation. Biomaterials 2013, 34, 8269–8278. [CrossRef] [PubMed]
7. Makadia, H.K.; Siegel, S.J. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery
carrier. Polymers 2011, 3, 1377–1397. [CrossRef] [PubMed]
8. Kobayashi, M.; Yamazaki, K.; Hirao, K.; Oishi, M.; Kanatsuka, A.; Yamauchi, M.; Takagi, H.; Kawai, K.;
Japan diabetes clinical data management study group. The status of diabetes control and antidiabetic drug
therapy in Japan—A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res.
Clin. Pract. 2006, 73, 198–204. [CrossRef] [PubMed]
9. Gelperina, S.; Kisich, K.; Iseman, M.D.; Heifets, L. The potential advantages of nanoparticle drug delivery
systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 2005, 172, 1487–1490. [CrossRef]
[PubMed]
10. Bucher, S.; Bauduceau, B.; Benattar-Zibi, L.; Bertin, P.; Berrut, G.; Corruble, E.; Danchin, N.; Delespierre, T.;
Derumeaux, G.; Doucet, J.; et al. Primary care management of non-institutionalized elderly diabetic patients:
The S.AGES cohort—Baseline data. Prim. Care Diabetes 2015, 9, 267–274. [CrossRef] [PubMed]
11. Cetin, M.; Sahin, S. Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride.
Drug Deliv. 2016, 23, 2796–2805. [CrossRef] [PubMed]
12. Andrews, M.; Soto, N.; Arredondo, M. Effect of metformin on the expression of tumor necrosis factor-α,
Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients. Rev. Med. Chile 2012, 140,
1377–1382. [CrossRef] [PubMed]
13. Koh, S.J.; Kim, J.M.; Kim, I.K.; Ko, S.H.; Kim, J.S. Anti-inflammatory mechanism of metformin and its effects
in intestinal inflammation and colitis-associated colon cancer. J. Gastroenterol. Hepatol. 2014, 29, 502–510.
[CrossRef] [PubMed]
14. Tanaka, H.; Nakai, K.; Murakami, F.; Morita, T.; Yamazaki, Y.; Matsuike, R.; Shibata, C.; Nagasaki, M.;
Kanda, M.; Tanabe, N.; et al. Ligature-induced periodontitis increased insulin resistance and triglyceride
levels in wistar rats. J. Hard. Tissue Biol. 2017, 26, 261–267. [CrossRef]
15. De Araújo, A.A.; Pereira AD SB, F.; de Medeiros CA, C.X.; de Castro Brito, G.A.; de Carvalho Leitão, R.F.;
de Souza Araújo, L.; Guedes, P.M.M.; Hiyari, S.; Pirih, F.Q.; de Araújo Júnior, R.F. Effects of metformin on
inflammation, oxidative stress, and bone loss in a rat model of periodontitis. PLoS ONE 2017, 12, e0183506.
[CrossRef] [PubMed]
16. Martinez, N.Y.; Andrade, P.F.; Duran, N.; Cavalitto, S. Development of double emulsion nanoparticles for the
encapsulation of bovine serum albumin. Colloids Surf. B Biointerfaces 2017, 158, 190–196. [CrossRef] [PubMed]
17. Iqbal, M.; Zafar, N.; Fessi, H.; Elaissari, A. Double emulsion solvent evaporation techniques used for drug
encapsulation. Int. J. Pharm. 2015, 496, 173–190. [CrossRef] [PubMed]
18. Miller, R.A.; Brady, J.M.; Cutright, D.E. Degradation rates of oral resorbable implants (polylactates and
polyglycolates): Rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 1977,
11, 711–719. [CrossRef] [PubMed]
19. Xu, Q.; Zhu, T.; Yi, C.; Shen, Q. Characterization and evaluation of metformin-loaded solid lipid nanoparticles
for celluar and mitochondrial uptake. Drug Dev. Ind. Pharm. 2016, 42, 701–706. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3488 16 of 16
20. Kamaly, N.; Xiao, Z.; Valencia, P.M.; Radovic-Moreno, A.F.; Farokhzad, O.C. Targeted polymeric therapeutic
nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 2012, 41, 2971–3010. [CrossRef]
[PubMed]
21. Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future
of nanomedicine? J. Control. 2016, 244 Pt A, 108–121. [CrossRef]
22. Kohane, D.S.; Langer, R. Polymeric biomaterials in tissue engineering. Pediatr. Res. 2008, 63, 487–491.
[CrossRef] [PubMed]
23. Goldberg, M.; Langer, R.; Jia, X. Nanostructured materials for applications in drug delivery and tissue
engineering. J. Biomater. Sci. Polym. Ed. 2007, 18, 241–268. [CrossRef] [PubMed]
24. Formariz, T.P.; Urban, M.C.C.; Silva Júnior, A.A.D.; Gremião, M.P.D.; Oliveira, A.G.D. Microemulsões e
fases líquidas cristalinas como sistemas de liberação de fármacos. Rev. Bras. Ciênc. Farm. 2005, 41, 301–313.
[CrossRef]
25. Vieira, D.B.; Gamarra, L.F. Advances in the use of nanocarriers for cancer diagnosis and treatment. Einstein
2016, 14, 99–103. [CrossRef] [PubMed]
26. Leonard, F.; Ali, H.; Collnot, E.M.; Crielaard, B.J.; Lammers, T.; Storm, G.; Lehr, C.M. Screening of budesonide
nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model. ALTEX
2012, 29, 275–285. [CrossRef] [PubMed]
27. Walsh, M.C.; Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond.
Front. Immunol. 2014, 5, 511. [CrossRef] [PubMed]
28. Bak, E.J.; Park, H.G.; Kim, M.; Kim, S.W.; Kim, S.; Choi, S.H.; Cha, J.H.; Yoo, Y.J. The effect of metformin
on alveolar bone in ligature-induced periodontitis in rats: A pilot study. J. Periodontol. 2010, 81, 412–419.
[CrossRef] [PubMed]
29. Liu, L.; Zhang, C.; Hu, Y.; Peng, B. Protective effect of metformin on periapical lesions in rats by decreasing
the ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin. J. Endod. 2012, 38, 943–947.
[CrossRef] [PubMed]
30. Najeeb, S.; Zafar, M.S.; Khurshid, Z.; Zohaib, S.; Madathil, S.A.; Mali, M.; Almas, K. Efficacy of metformin in
the management of periodontitis: A systematic review and meta-analysis. Saudi Pharm. J. 2018, 26, 634–642.
[CrossRef] [PubMed]
31. Jeyabalan, J.; Shah, M.; Viollet, B.; Chenu, C. AMP-activated protein kinase pathway and bone metabolism.
J. Endocrinol. 2012, 212, 277–290. [CrossRef] [PubMed]
32. LeBrasseur, N.K.; Kelly, M.; Tsao, T.S.; Farmer, S.R.; Saha, A.K.; Ruderman, N.B.; Tomas, E. Thiazolidinediones
can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab.
2006, 291, E175–E181. [CrossRef] [PubMed]
33. Kanazawa, I.; Yamaguchi, T.; Yano, S.; Yamauchi, M.; Sugimoto, T. Metformin enhances the differentiation
and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2
expression. Biochem. Biophys. Res. Commun. 2008, 375, 414–419. [CrossRef] [PubMed]
34. Lee, Y.-S.; Kim, Y.-S.; Lee, S.-Y.; Kim, G.H.; Kim, B.J.; Lee, S.H.; Lee, K.U.; Kim, G.S.; Kim, S.W.; Koh, J.M. AMP
kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 2010, 47, 926–937.
[CrossRef] [PubMed]
35. Mizukami, J.; Takaesu, G.; Akatsuka, H.; Sakurai, H.; Ninomiya-Tsuji, J.; Matsumoto, K.; Sakurai, N. Receptor
activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through
a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 2002, 22, 992–1000. [CrossRef]
[PubMed]
36. Zhou, Z.; Han, J.-Y.; Xi, C.-X.; Xie, J.X.; Feng, X.; Wang, C.Y.; Mei, L.; Xiong, W.C. HMGB1 regulates
RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J. Bone Miner. Res. 2008, 23, 1084–1096.
[CrossRef] [PubMed]
37. Palamoor, M.; Jablonski, M.M. Comparative study on diffusion and evaporation emulsion methods used
to load hydrophilic drugs in poly(ortho ester) nanoparticle emulsions. Powder Technol. 2014, 253, 53–62.
[CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
